Skip to main content
. 2019 Jan 15;10(2):36. doi: 10.1038/s41419-018-1285-3

Fig. 8. Ferumoxytol-magnetic resonance imaging (MRI) can be an imaging biomarker for CD47 immunotherapy.

Fig. 8

The signal-regulatory protein alpha (SIRPα) surface marker on osteosarcoma cells inhibits macrophage phagocytosis. Blocking the CD47–SIRPα interaction with CD47 monoclonal antibody (mAb) induces phagocytosis of both tumor and ferumoxytol nanoparticles. Increased uptake of ferumoxytol nanoparticles generates T2 contrast on MR scans that can serve as an imaging biomarker for monitoring responses to CD47 immunotherapy